Phase I oral safety assessment of a novel antifungal for systemic fungal infections

A new oral antifungal drug, developed by F2G, is about to be tested for safety in healthy volunteers for the first time. This matters because systemic fungal infections—caused by yeasts and moulds—are life-threatening for people with weakened immune systems, such as those undergoing chemotherapy or organ transplants. The number of patients is rising, yet doctors currently have only three classes of antifungal drugs to choose from. These existing options often cause severe side effects or cannot be taken alongside other essential medicines. F2G’s drug works through a completely different mechanism and is highly potent against many of the moulds responsible for these serious infections. If this oral safety assessment succeeds, the drug can move into trials with patients who have active infections. The potential impact is a new treatment option that is safer, more compatible with other medications, and effective against drug-resistant strains. For patients with compromised immunity, this could mean the difference between surviving a routine fungal infection and dying from it. The project does not address fundamental science—it is a targeted, late-stage drug development effort aimed directly at an urgent clinical need.